​History & Milestones

+ 43 1 7489500 

NBS-C  BioScience

​​

2021:


  • NBS-C BioScience and APEIRON Biologics AG sign a Material Transfer and Evaluation Agreement to evaluate in-vitro potency of APEIRON's COVID-19 drug candidate APN01 against a series of mutant SARS-CoV-2 Spike Protein Variants including virus mutants with increased infectivity recently identified in Great Britain and South Africa. 


2020:


  • ​Establishment of an interdisciplinary SARS-CoV-2 SPR platform which addresses molecular and functional characterization of drug - target interactions for SARS-CoV-2 related R&D projects as well as qualitative and quantitative analysis of polyclonal antibody responses to SARS-CoV-2 infection and vaccine candidates. The project is supported by Österreichische Forschungsförderungsgesellschaft (FFG), Emergency Call Grant No. 35907826.
  • NBC-BioScience and VelaLabs GmbH Vienna, a GLP certified Member of Tentamus Group, renew their Cooperation ​Agreement allowing NBS-C BioScience to conduct R&D projects, e.g. development of biosimilars and new biological drugs, from basic research, lead optimization and assay development to GLP controlled clinical development through a well established routine transfer process.


2018:


  • Publication of patent application PCT/EP2018/063245, disclosing a new molecular target for detection of compounds for treatment of neuropathic pain and other disorders, discovered by NBS-C BioScience in contract Research for NovAssay SA, Switzerland / London, UK.
  • NBSC-BioScience enters collaboration with Laboratorio Reig Jofre SA, Barcelona, Spain.
  • NBS-C BioScience and AVVA Pharmaceuticals, Cyprus, establish a five year Service Level Agreement.


2017:


  • NBS-C BioScience and JHL Biotech Inc., Taiwan, enter extensive R&D project collaboration aiming at the development of a monoclonal antibody biosimilar.
  • Patent PCT/EP2014/077937; WO2015 / 091463, is granted in US and processed worldwide.
  • NBS-C BioScience moves to its new location in Schuhfabrikgasse 17, 1230 Vienna.


2016:


  • NBS-C BioScience signs  a CRO Frame Contract with Mosaic Biomedicals SL, Barcelona, Spain, to accompany development of a novel therapeutic monoclonal antibody through all pre-clinical stages, establish a GxP validated SPR based identity / potency assay for clinical sample measurement and batch release during clinical development phases.


2015:


  • Publication of patent application PCT/EP2014/077937, disclosing a new chemical compound for treatment of neuropathic pain and other disorders, displaying a novel mode of action discovered by NBS-C BioScience in contract Research for NovAssay SA, Switzerland / London, UK.


2014:


  • Key data generated at NBS-C BioScience during a research cooperation with the  Institute of Molecular Biotechnology, Vienna (IMBA)  are published in Nature 511, 104-107.


2013:


  • NBS-C BioScience and Fresenius Kabi, Germany, sign a five year CRO frame contract.
  • NBS-C BioScience and Bind Therapeutics Inc., Cambridge, MA, sign a five year CRO Service Level agreement for development of a nanoparticle based oncological therapeutic. 
  • NBS-C BioScience and Harvard Medical School, Children‘s Hospital, initiate collaboration.
  • The service level contract with Baxter Innovations is prolonged for another two year period.


2011:


  • NBS-C BioScience signs a two year service level contract with Baxter Innovations Austria.
  • NBS-C BioScience moves into its new location at the site of the partner company Vela Laboratories, located in Vienna, Brunnerstrasse 69. This merger of company sites opens a wide field of intensified synergies of mutual benefit.
  • NBS-C BioScience successfully completes its research project "Anti-Idiotype Vaccine for IgE induced Diseases" by achieving all pre-defined milestones, demonstrating Proof of Strategic Concept and generating two protective prototype immunogens with the potential to be developed as anti-allergy vaccine.


2010:

  • NBS-C BioScience signs a partnership agreement with Vela Laboratories, a Viennese GMP-certified contract laboratory offering protein characterisation services (Biopharmaceuticals, Biologics, Biogenerics / Biosimilars) in all stages of product development (pre-clinical, clinical) up to market approval. This agreement provides a platform for mutual project exchange and collaboration, thus opening access to a fully functional GxP environment for NBS-C BioScience projects.
  • NBS-C BioScience wins a Science 2Business Award price, presented by the Austrian Ministery of Economics for the best and most creative cooperations between industry and science. 27 applicants with 175 cooperation partners from 12 nations participated in the competition.
  • Together with GE Healthcare, NBS-C BioScience organizes the 1st Vienna Biacore / MicroCal User Day on March 16th, 2010, at the    NBS-C BioScience site located at the  Biotech Competence Center in Vienna. The purpose of the meeting was to bring together experienced users and researchers interested in  the field of surface plasmon resonance and microcalorimetry as versatile tools for studying the biophysical characteristics of molecular interactions.


2009:

  • NBS-C obtains worldwide exclusive license to manufacture and commercialize monoclonal antibodies and other recombinant proteins originating from the Institute of Immunology, University Bern, Switzerland, to be developed and brought to market as Allergy Research Tools and Diagnostics.
  • Prof. Beda M. Stadler, Director of the Institute of Immunology, University Bern, Switzerland, joins as Scientific Advisor.
  • NBS-C BioScience & Consulting GmbH is founded by a group of scientists from Novartis Institutes for BioMedical Research, Vienna, AT, and Horsham, UK. Initiation of the project "Anti-Idiotype Vaccine for IgE Induced Diseases", winner of call CoOperate 08, funded by Zentrum für Innovation und Technologie (ZIT), Vienna.